VCYT:NSD-Veracyte Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 34.98

Change

+0.67 (+1.95)%

Market Cap

USD 2.59B

Volume

0.69M

Analyst Target

USD 38.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-2.76 (-0.66%)

USD 34.17B
ILMN Illumina Inc

+3.73 (+2.49%)

USD 23.86B
ICLR ICON PLC

-1.60 (-0.73%)

USD 18.82B
NTRA Natera Inc

-0.72 (-0.58%)

USD 15.36B
EXAS EXACT Sciences Corporation

+1.33 (+1.91%)

USD 13.02B
MEDP Medpace Holdings Inc

-1.60 (-0.50%)

USD 9.93B
RDNT RadNet Inc

+1.45 (+2.18%)

USD 5.00B
SHC Sotera Health Co

-0.06 (-0.38%)

USD 4.49B
NEOG Neogen Corporation

-0.01 (-0.07%)

USD 3.13B
GH Guardant Health Inc

+0.60 (+2.61%)

USD 2.52B

ETFs Containing VCYT

ARCG:LSE ARK Genomic Revolution UC.. 4.67 % 0.00 %

+4.80 (+1.42%)

USD 3.68M
ARKG:LSE ARK Genomic Revolution UC.. 4.67 % 0.00 %

+0.06 (+1.42%)

USD 3.68M
GNOG:LSE Global X Genomics & Biote.. 4.50 % 0.00 %

+0.06 (+1.42%)

USD 5.77M
GN0M:XETRA Global X Genomics & Biote.. 4.37 % 0.00 %

+0.08 (+1.42%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.37 % 0.00 %

+0.05 (+1.42%)

USD 5.93M
WBIO:LSE WisdomTree BioRevolution .. 1.90 % 0.00 %

+8.10 (+1.42%)

USD 3.58M
WRNA:XETRA WisdomTree BioRevolution .. 1.86 % 0.00 %

+0.03 (+1.42%)

USD 2.77M
WDNA 1.81 % 0.00 %

N/A

N/A
ARKG 0.00 % 0.75 %

N/A

N/A
ETHO Amplify ETF Trust 0.00 % 0.45 %

+0.12 (+1.42%)

USD 0.18B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.13 (+1.42%)

USD 0.08B
ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

+0.03 (+1.42%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.15% 60% D- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.15% 60% D- 71% C-
Trailing 12 Months  
Capital Gain 47.59% 60% D- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.59% 60% D- 71% C-
Trailing 5 Years  
Capital Gain 46.85% 67% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.85% 67% D+ 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 9.63% 58% F 61% D-
Dividend Return 9.63% 58% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.96% 56% F 36% F
Risk Adjusted Return 17.85% 72% C 52% F
Market Capitalization 2.59B 80% B- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector